IceCure code request rejected; ~$4,000 facility fee stays

The temporary CPT category III code remains in place, allowing facilities to receive approximately $4,000 for the ProSense procedure facility fee.

Rhea-AI Filing Summary

IceCure Medical Ltd. said the American Medical Association’s CPT Editorial Panel did not approve its request to replace the temporary CPT category III code for cryoablation of cancerous breast tumors with a permanent category I code. The panel determined the transition was premature after reviewing the application at its September 2026 meeting.

The existing temporary code remains in place, allowing facilities to be paid by CMS approximately $4,000 for the ProSense procedure facility fee. The decision does not affect IceCure’s ability to continue commercial activities under the existing reimbursement framework. The company may resubmit its request in June 2027.

Key Figures

Facility fee: Approximately $4,000 Application submitted: June 2026 CPT Editorial Panel meeting: September 2026 +1 more

4 metrics

Facility fee Approximately $4,000 For the ProSense procedure under the existing CPT category III code

Application submitted June 2026 Request for a permanent CPT category I code

CPT Editorial Panel meeting September 2026 The panel reviewed the company’s application

Potential resubmission June 2027 Potential resubmission of the CPT category I code request

Key Terms

CPT category I code, CPT category III code, cryoablation, facility fee, +1 more

5 terms

CPT category I code regulatory

"permanent CPT category I code"

CPT category III code regulatory

"temporary CPT category III code"

A CPT Category III code is a temporary medical billing code created and maintained by the American Medical Association to identify emerging technologies, new procedures, and novel services for data collection and tracking. The codes use a five-character format with a trailing 'T' (e.g., 0123T), are intended to record clinical use and outcomes while evidence and acceptance are developing, and typically expire or are reviewed after a set period (commonly five years) unless converted to a permanent Category I code or renewed. These codes do not by themselves establish routine coverage or payment; payers decide separately whether and how to reimburse services billed with them.

cryoablation medical

"use of cryoablation for treating cancerous breast tumors"

A medical treatment that uses extreme cold to freeze and destroy unwanted tissue, such as small tumors or heart tissue causing irregular rhythms; think of it like applying a focused freezer to stop a problem spot without cutting it out. It matters to investors because devices, tools, and drugs tied to cryoablation, plus clinical results, approval status and insurance coverage, can drive sales, shape market adoption and affect the financial outlook of healthcare companies.

facility fee financial

"approximately $4,000 for the facility fee"

A facility fee is a charge billed by a hospital or clinic for use of its buildings, equipment and support services when a patient receives care, separate from the fee paid to the treating doctor. For investors, it matters because these charges are a steady revenue stream that can boost margins and cash flow, but they are also sensitive to changes in insurance reimbursement rules and regulatory scrutiny—think of it as a venue rental fee separate from the performer’s paycheck.

CPT Editorial Panel regulatory

"decision of its CPT Editorial Panel"

The CPT Editorial Panel is the committee that reviews and approves changes to CPT codes, the standardized codes used to describe medical procedures and services for billing and insurance. Investors should care because new or revised codes determine how and whether healthcare providers get paid for procedures, which can speed or slow adoption of treatments and affect revenue streams for device makers, drug developers and healthcare services—like updating a store catalog that decides which products can be sold and reimbursed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the AMA decide about ICCM’s CPT code request?

The CPT Editorial Panel determined on October 2, 2026, that transition to a permanent CPT category I code was premature and did not approve IceCure Medical’s request. The temporary CPT category III code remains in place.

What reimbursement remains for the ICCM ProSense procedure?

The existing temporary CPT category III code allows facilities to be paid by CMS approximately $4,000 for the ProSense procedure facility fee.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 06:30 AM Accepted by SEC EDGAR 10/05/2026 - 06:30 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934

For the Month of October 2026

Commission File Number: 001-40753

ICECURE MEDICAL Ltd.
(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163
Caesarea, 3079504 Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒            Form 40-F ☐

CONTENTS

In June 2026, IceCure Medical Ltd. (the “Company”) submitted an application to the American Medical Association for a permanent Current Procedural Terminology (“CPT”) category I code to replace the currently in-place CPT category III code describing the use of cryoablation for treating cancerous breast tumors. The American Medical Association reviewed the Company’s application during its September 2026 CPT Editorial Panel meeting, where the Company and supporting medical societies provided information, support and advocated for the requested transition from the current CPT category III code to a permanent CPT category I code. On October 2, 2026, the American Medical Association published the decision of its CPT Editorial Panel, which determined that the transition to a permanent CPT category I code is premature at this time and it did not approve the Company’s requested change. The decision by the American Medical Association’s CPT Editorial Panel provides additional time for the Company to continue expanding clinical evidence, increasing utilization of the Company’s ProSense system, and working closely with leading medical societies toward a potential resubmission of the CPT category I code request in June 2027.

The decision of the American Medical Association’s CPT Editorial Panel has no impact on the temporary CPT Category III code, which remains in place and allows facilities to be paid by Centers for Medicare and Medicaid Services (“CMS”) for the ProSense procedure at approximately $4,000 for the facility fee, and does not affect the Company’s ability to continue its commercial activities under the existing CPT Category III reimbursement framework with CMS.

Incorporation by Reference

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-297030, 333-290046 and 333-258660) and Form S-8 (333-298361, 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission (the “SEC”), to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Forward-Looking Statements

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. For example, the Company is using forward-looking statements when it discusses its expectations with respect to the potential resubmission to the American Medical Association of an application for a CPT category I code request in June 2027. All statements other than statements of historical facts included in this Report of Foreign Private Issuer on Form 6-K are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include the risks and uncertainties described in the Company’s annual report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s other filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IceCure Medical Ltd.
Date: October 5, 2026	By:	/s/ Eyal Shamir
	Name:	Eyal Shamir
	Title:	Chief Executive Officer

2